Anticancer

Cycloartane-3,24,25-triol
Catalog No: CFN98972

Cycloartane-3,24,25-triol has potential for development as an anti-cancer agent against prostate cancer. It reduces the viability of PC-3 and DU145 cell lines with IC50 values of 2.226 ± 0.28 μM and 1.67 ± 0.18 μM respectively.

Norcepharadione B
Catalog No: CFN98975

Norcepharadione B shows good inhibitory activity against the replication of HSV-1, it also shows antimalarial activity with EC50 values of 7.5mug/ml. Norcepharadione B exhibits significant cytotoxicity against five human tumor cell lines (A-549, SK-OV-3, SK-MEL-2, XF-498 and HCT-15) in vitro. Norcepharadione B shows significant inhibitory effects on both ADP-induced and thrombin-induced platelet aggregation.

Convolvine
Catalog No: CFN00186

Convolvine and its derivatives exhibit pronounced antihypoxic, immunomodulating, and anti-inflammatory activity, they exhibit cytotoxic activity, the alkaloids N-benzylconvolvine and N-chloroacetylconvolvine at concentrations of 10 ug/mL exhibit the greatest activity against HeLa and Hep cancer cell cultures. Convolvine blocks the M-receptors of the heart and intestine but raises the sensitivity of the M-receptors of the salivary gland and of the CNS,convolvine has revealed characteristics of a sedative and nootropic agent.

Matairesinol
Catalog No: CFN98983

Matairesinol has radical and superoxide scavenging activities,; it also has anti-angiogenic activity by suppressing mROS signaling , can decrease hypoxia-inducible factor-1α in hypoxic HeLa cells.Matairesinol has anti-osteoporotic activity via p38/ERK-NFATc1 signaling, but not by way of anti-resorptive action. Matairesinol could markedly benefit TRAIL-based tumor therapies, including those aimed at prostate cancer.

Gomisin A
Catalog No: CFN98990

Gomisin A has anti-inflammatory, antihypertensive, neuroprotective, and anti-proliferation properties, it induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. Gomisin A inhibits COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation.